← Back to Search

Monoclonal Antibodies

Eptinezumab 300 mg for Migraine (DELIVER Trial)

Phase 3
Waitlist Available
Research Sponsored by H. Lundbeck A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
Awards & highlights

DELIVER Trial Summary

This trial is testing a new drug to see if it can help people with migraines who haven't had success with other preventive treatments.

Eligible Conditions
  • Migraine

DELIVER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12
Secondary outcome measures
Change From Baseline in HIT-6 Score at Weeks 36, 48, 60, and 72
Change From Baseline in the HIT-6 Score at Week 24
Change From Baseline in the Headache Impact Test (HIT-6) Score at Week 12
+37 more

Side effects data

From 2020 Phase 3 trial • 485 Patients • NCT04152083
2%
Hypersensitivity
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Eptinezumab

DELIVER Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Eptinezumab 300 mgExperimental Treatment1 Intervention
Participants will receive eptinezumab 300 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
Group II: Eptinezumab 100 mgExperimental Treatment1 Intervention
Participants will receive eptinezumab 100 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive placebo matching to eptinezumab by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Eptinezumab
2021
Completed Phase 3
~2040

Find a Location

Who is running the clinical trial?

H. Lundbeck A/SLead Sponsor
325 Previous Clinical Trials
76,691 Total Patients Enrolled
12 Trials studying Migraine
3,894 Patients Enrolled for Migraine
Email contact via H. Lundbeck A/SStudy DirectorLundbeckClinicalTrials@Lundbeck.com
188 Previous Clinical Trials
57,448 Total Patients Enrolled
11 Trials studying Migraine
3,396 Patients Enrolled for Migraine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
2020. "A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04418765.
~185 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top